Latest News
Oct 22, 2018

Oct. 22, 2018 In response to multiple inquiries received regarding the status of Mylan’s Abbreviated New Drug Application for generic Advair® (Wixela®), Mylan confirms it has not received any...

Oct 19, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets...

Oct 19, 2018

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...

Oct 18, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial, a generic version of...

Oct 18, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2018 financial results, on Mon., Nov. 5, after the close of the U.S. financial...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected